Veracyte Announces Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise as markets stabilise, dollar set for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
Veracyte (VCYT) Tops Q3 EPS by 13c, Revenues Beat; Boosts FY18 Revenue Outlook
October 29, 2018 4:30 PM EDTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.12), $0.13 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $21.5 million.
Revenue was $23.5 million, an increase of 34 percent;Genomic test volume was 8,006, an increase of 23 percent;Gross margin was 65 percent, an increase of 6 percent;Operating expenses,... More


